Introduction
There is now no doubt that patients with localized Hodgkin's disease should be treated with intensive wide-field radiotherapy. Indeed most of these patients may be cured if this is done (Peters and Middlemiss, 1958; Easson, 1966; Kaplan, 1966; Peters et al., 1966) . At the time of presentation, however, some patients have disseminated disease and others have recurrence in previously irradiated areas, making further radiotherapy impossible, and it is in these circumstances that chemotherapy may prove extremely valuable.
Until recently we used the effective drugs, such as the nitrogen mustards (mustine hydrochloride, chlorambucil, cyclophosphamide), vinblastine, and procarbazine, as single agents. We found that definite objective improvement occurred in about 70% of the patients (Fairley et al., 1966) . Lacher and Durant (1965) , however, using a combination of vinblastine and chlorambucil, obtained complete remissions in 63 % and partial remissions in a further 18% of patients with disseminated Hodgkin's disease. At the National Cancer Institute, Bethesda, Carbone and his colleagues (Perry et al. 1967; De Vita et al., 1969) , using four agents simultaneouslyprednisone, vincristine, nitrogen mustard, and procarbazine-t Registrar in Medicine, St (Bernard et al., 1967; Goguel et al., 1969) . Because these results were so much better than those obtained with single agents, we have been using combination chemotherapy for the past two years. The purpose of this paper is to record our results and to discuss their significance.
Patients and Methods
The diagnosis was established by histological examination of biopsy material in all the patients and classified by a slight modification of the classification of Lukes and Butler (1966) as shown in Table I . The extent of the disease was assessed immediately before combination chemotherapy by clinical examination, chest x-ray films including hilar tomography, lymphangiography, aspiration bone marrow biopsy, and liver function tests; in some patients liver scan and liver biopsy were also carried out. The patients were then classified according to the Rye staging (Peters et al., 1966) If the systemic symptoms of fever, sweating, pruritus, and loss of weight were absent the patients were classified as "A" and if present as "B." Table II Vinblastine 10 mg. (for an adult patient) intravenously on Days 0, 7, and 14.
Mustine hydrochloride 6 mg./sq. m. on Days 0 and 7.
In this series 52 patients were treated exclusively with our regimen. Three were initially treated with the regimen of Carbone (Perry et al., 1967) , but after receiving two courses they were changed to our regimen.
The two essential aims in using chemotherapy in disseminated Hodgkin's disease are, firstly, to produce complete or, failing this, partial remissions; and, secondly, to maintain these remissions for as long as possible. De Vita et al. (1969) showed that even if complete remissions were obtained with six courses of combination chemotherapy, and no further treatment was given, relapses occurred. It is therefore now our policy to give six courses of treatment, leaving four weeks between each course. If at the end of this time there are still signs of disease, further courses are given, preferably at monthly intervals; or if the patients are completely unresponsive, other agents such as 1,3-bis-(2 chloroethyl)-l-nitrosourea or bleomycin are used. Patients who are in complete remission after their first six courses are then given courses at three-monthly intervals for one year and at four-monthly intervals for the next year.
The definition of complete and partial remission is difficult. We therefore have three categories.
(1) Complete Remission (apparently free from disease).-This means the absence of all detectable disease on clinical examination, chest radiography (including tomography), rescreening of the abdomen in cases where sufficient dye remains after previous lymphangiography, and the return of liver function tests to normal. In addition there must be complete relief of systemic symptoms.
(2) Partial Remission.-Objective improvement in the size of glandular masses, hepatosplenomegaly, or infiltrations elsewherefor example, bone or lung-with or without relief of systemic symptoms.
(3) Active Disease.-Progression of the disease.
*Given only with the first and fourth courses.
BRmSH MEDICAL JOURNAL Results The results are summarized in the Charts, in which the patients have been divided into three groups: those who had never been treated before-that is, the disease was stage III or IV at the time of presentation; those who had received only radiotherapy; and those who had previously received chemotherapy with or without radiotherapy. The number of patients achieving oomplete remission at some time during their treatment, and the response at the time of analysis, are summarized in Table III.   TABLE III Of the seven patients who had not received any previous treatment a complete remission was obtained in six, of whom five are still without evidence of disease from 2 to 20 months after the onset of combination chemotherapy. Unfortunately, in one patient the complete remission was short-lived, and she died 16 months after the beginning of chemotherapy (Case 47). The remaining patient is in partial remission 21 months after beginning treatment, and the only evidence of activity is a raised serum alkaline phosphatase, which could in fact be due to chronic biliary,obstruction following surgery to the gall bladder, and not Hodgkin's disease (Case 48).
Of the 19 patients who had received only radiotherapy in the past 15 went into complete remission and 12 are still without evidence of disease 4 to 18 months after the onset of combination chemotherapy. Of the remaining three, two are dead-one (Case 29) died from bronchopneumonia between the sixth and seventh courses of combination chemotherapy, and at necropsy there was no evidence of Hodgkin's disease; the other (Case 36) died between the second and third rourses of treatment from bronchopneumonia, generalized herpes zoster, and acute polyneuritis. At the time this occurred his blood count was normal, and the overwhelming infection could not be attributed to bone marrow failure or to the lack of circulating immunoglobulins or lymphocytes, as these were all normal. in this group: the first had Hodgkin's disease arising in the stomach and was difficult to classify histologically; the second had a lymphocytic-predominant picture with large bizarre reticulum cells but no classical Reed-Sternberg cells, and one of us (A.G.S.) thought this was best classified as Hodgkin's disease; and their third showed different histological patterns at different sites, the mediastinal lymph node biopsy showing nodular sclerosis, and the cervical lymph node biopsy showing mixed cellularity, despite the fact that these two biopsies were taken at the same time.
The correlation between the stage of the disease and the initial response to combination chemotherapy is shown in Table II . The only patients who failed to respond at all were four with stage IVB disease. Table IV shows the correlation between the initial response and the presence of systemic symptoms; the response, as expected, being much better in those without symptoms. These results raise another and very important problem in the treatment of Hodgkin's disease-that is, the indication for using chemotherapy as opposed to radiotherapy. Everyone is now agreed that stage I and stage II disease must be treated with high-dosage large-field irradiation, and that stage IV disease should be treated with chemotherapy. The problem centres on the treatment of patients with stage III disease. Smithers (1969) recommended treating with radiotherapy patients having stage IIIA disease, and Kaplan (1968) included IIIB as well. Others are still treating stage III disease with chemotherapy. Certainly the initial response to combination chemotherapy in those patients in whom chemotherapy is being used for the first time compares very favourably with that of Kaplan's patients treated with radiotherapy, but it remains to be seen which group will have the better ultimate prognosis. A controlled trial of the two forms of treatment in stage III is highly desirable.
Introduction
There appears to be a continuing demand for sedation or general anaesthesia for conservative dentistry, but to what extent this is due to publicity which has not indicated adequately the hazards involved is still not clear (Central Health Services Council, 1967) . It seems likely that the safest and most satisfactory method of meeting this demand will be in the use of potent but short-acting tranquilizers rather than anaesthetics. Clinical reports on the use of intravenous diazepam for this purpose have already been published (Poswillo, 1967; Healy, Edmondcon, and Hall, 1970; MacDonald and Carmichael, 1970) . Though a report of the cardiovascular and respiratory effects of diazepam has been published (Dalen et al., 1969) 
